dc.contributor.author | Fossmark, Reidar | |
dc.contributor.author | Olaisen, Maya | |
dc.contributor.author | Martinsen, Tom Christian | |
dc.contributor.author | Melberg, Hans Olav | |
dc.date.accessioned | 2021-10-13T06:25:19Z | |
dc.date.available | 2021-10-13T06:25:19Z | |
dc.date.created | 2021-07-21T13:46:05Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Therapeutic Advances in Gastroenterology. 2021, 14 1-10. | en_US |
dc.identifier.issn | 1756-283X | |
dc.identifier.uri | https://hdl.handle.net/11250/2789481 | |
dc.description.abstract | Background: Oral 5-aminosalicylic acid (5-ASA) is the mainstay treatment of ulcerative colitis (UC) and therapy with oral 5-ASA is associated with beneficial outcomes. We have examined factors associated with the persistence of oral 5-ASA treatment in a national cohort of UC patients. Methods: Patients with newly diagnosed UC from 2010 to 2014 using oral 5-ASA monotherapy were identified by combining data from the Norwegian Patient Registry and the Norwegian Prescription Database. The median follow-up time was 1029 days. Drug persistence was defined as duration of oral 5-ASA preparation as monotherapy. Non-persistence of a oral 5-ASA preparation as monotherapy was defined as stopping oral 5-ASA, initiation of any further anti-inflammatory treatment including a course of glucocorticoids and a change to another oral 5-ASA preparation. Drug persistence was analyzed using the Kaplan–Meier method and influence of covariates on drug persistence was analyzed with the Cox proportional hazard model. Results: A total of 3421 patients were identified. The overall median 5-ASA drug persistence was 179 days. In univariate analyses, persistence was associated with preparation type and high-dose treatment, while oral glucocorticoid use or hospitalization around the start of oral 5-ASA were associated with shorter 5-ASA persistence. In multivariate analyses, oral glucocorticoids [HR 1.67 (1.54–1.80), p < 0.005] and hospitalization around start of 5-ASA [HR 1.23 (1.14–1.34), p < 0.005] were associated with non-persistence, whereas high dose (⩾3 g/day) 5-ASA was associated with longer persistence [HR 0.68 (0.65–0.71), p < 0.005]. Conclusion: High-dose treatment with oral 5-ASA was associated with longer persistence of oral 5-ASA monotherapy, whereas the presence of factors indicating more severe disease around initiation of 5-ASA monotherapy was associated with a shorter persistence. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Sage | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 1-10 | en_US |
dc.source.volume | 14 | en_US |
dc.source.journal | Therapeutic Advances in Gastroenterology | en_US |
dc.identifier.doi | 10.1177/17562848211021760 | |
dc.identifier.cristin | 1922345 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |